Cargando…
Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana
It is established that addition of systemic therapy to locoregional treatment for breast cancer improves survival. However, reliable data are lacking about the outcomes of such treatment in women with breast cancer in low middle-income countries. We compared the outcomes of treatment in patients who...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457842/ https://www.ncbi.nlm.nih.gov/pubmed/34156868 http://dx.doi.org/10.1200/GO.20.00664 |
_version_ | 1784571189928132608 |
---|---|
author | Ayettey Anie, Hannah Yarney, Joel Sanuade, Olutobi Awasthi, Shivanshu Ndanu, Tom Akuetteh Parekh, Akash D. Aidoo, Charles Dadzie, Mary Ann Vanderpuye, Verna Yamoah, Kosj |
author_facet | Ayettey Anie, Hannah Yarney, Joel Sanuade, Olutobi Awasthi, Shivanshu Ndanu, Tom Akuetteh Parekh, Akash D. Aidoo, Charles Dadzie, Mary Ann Vanderpuye, Verna Yamoah, Kosj |
author_sort | Ayettey Anie, Hannah |
collection | PubMed |
description | It is established that addition of systemic therapy to locoregional treatment for breast cancer improves survival. However, reliable data are lacking about the outcomes of such treatment in women with breast cancer in low middle-income countries. We compared the outcomes of treatment in patients who had received neoadjuvant chemotherapy (NACT) or adjuvant chemotherapy and examined the factors associated with breast cancer recurrence and survival at the National Radiotherapy Oncology and Nuclear Medicine Centre, Korle Bu Teaching Hospital, Ghana. METHODS: This was a retrospective cohort study. The medical charts of women with breast cancer managed at the National Radiotherapy Oncology and Nuclear Medicine Centre from 2005 to 2014 were reviewed. A total of 388 patients with a median follow-up of 48 months were included in the study. Logistic regression was used to estimate the risk of recurrence. Survival was estimated using cox proportional hazards model. All models were adjusted with clinicopathologic variables. A P value of < .05 was considered statistically significant. RESULTS: Fifty-nine percent received adjuvant chemotherapy. In an adjusted logistic model, no difference was observed in locoregional recurrence between patients receiving NACT compared with those receiving adjuvant chemotherapy (odds ratio = 1.05; 95% CI, 0.44 to 2.47). However, NACT recipients had a higher likelihood of distant recurrence (odds ratio = 1.97; 95% CI, 1.24 to 3.15). In a multivariable analysis, no differences were observed in overall survival between the two chemotherapy groups (hazard ratio = 1.43; 95% CI, 0.91 to 2.26). CONCLUSION: NACT yields similar outcomes compared with adjuvant chemotherapy; however, recipients of NACT with advanced disease may have more distant failures. Early detection in a resource-limited setting is therefore crucial to optimal outcomes, significantly limiting recurrence and improving survival. |
format | Online Article Text |
id | pubmed-8457842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-84578422021-09-23 Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana Ayettey Anie, Hannah Yarney, Joel Sanuade, Olutobi Awasthi, Shivanshu Ndanu, Tom Akuetteh Parekh, Akash D. Aidoo, Charles Dadzie, Mary Ann Vanderpuye, Verna Yamoah, Kosj JCO Glob Oncol ORIGINAL REPORTS It is established that addition of systemic therapy to locoregional treatment for breast cancer improves survival. However, reliable data are lacking about the outcomes of such treatment in women with breast cancer in low middle-income countries. We compared the outcomes of treatment in patients who had received neoadjuvant chemotherapy (NACT) or adjuvant chemotherapy and examined the factors associated with breast cancer recurrence and survival at the National Radiotherapy Oncology and Nuclear Medicine Centre, Korle Bu Teaching Hospital, Ghana. METHODS: This was a retrospective cohort study. The medical charts of women with breast cancer managed at the National Radiotherapy Oncology and Nuclear Medicine Centre from 2005 to 2014 were reviewed. A total of 388 patients with a median follow-up of 48 months were included in the study. Logistic regression was used to estimate the risk of recurrence. Survival was estimated using cox proportional hazards model. All models were adjusted with clinicopathologic variables. A P value of < .05 was considered statistically significant. RESULTS: Fifty-nine percent received adjuvant chemotherapy. In an adjusted logistic model, no difference was observed in locoregional recurrence between patients receiving NACT compared with those receiving adjuvant chemotherapy (odds ratio = 1.05; 95% CI, 0.44 to 2.47). However, NACT recipients had a higher likelihood of distant recurrence (odds ratio = 1.97; 95% CI, 1.24 to 3.15). In a multivariable analysis, no differences were observed in overall survival between the two chemotherapy groups (hazard ratio = 1.43; 95% CI, 0.91 to 2.26). CONCLUSION: NACT yields similar outcomes compared with adjuvant chemotherapy; however, recipients of NACT with advanced disease may have more distant failures. Early detection in a resource-limited setting is therefore crucial to optimal outcomes, significantly limiting recurrence and improving survival. Wolters Kluwer Health 2021-06-22 /pmc/articles/PMC8457842/ /pubmed/34156868 http://dx.doi.org/10.1200/GO.20.00664 Text en © 2021 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | ORIGINAL REPORTS Ayettey Anie, Hannah Yarney, Joel Sanuade, Olutobi Awasthi, Shivanshu Ndanu, Tom Akuetteh Parekh, Akash D. Aidoo, Charles Dadzie, Mary Ann Vanderpuye, Verna Yamoah, Kosj Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana |
title | Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana |
title_full | Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana |
title_fullStr | Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana |
title_full_unstemmed | Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana |
title_short | Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana |
title_sort | neoadjuvant or adjuvant chemotherapy for breast cancer in sub-saharan africa: a retrospective analysis of recurrence and survival in women treated for breast cancer at the korle bu teaching hospital in ghana |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457842/ https://www.ncbi.nlm.nih.gov/pubmed/34156868 http://dx.doi.org/10.1200/GO.20.00664 |
work_keys_str_mv | AT ayetteyaniehannah neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana AT yarneyjoel neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana AT sanuadeolutobi neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana AT awasthishivanshu neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana AT ndanutomakuetteh neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana AT parekhakashd neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana AT aidoocharles neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana AT dadziemaryann neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana AT vanderpuyeverna neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana AT yamoahkosj neoadjuvantoradjuvantchemotherapyforbreastcancerinsubsaharanafricaaretrospectiveanalysisofrecurrenceandsurvivalinwomentreatedforbreastcanceratthekorlebuteachinghospitalinghana |